Covers the development of more selective therapies allowed by a new understanding of the mechanisms of molecular pathogenesis of chronic myelogenous leukemia; presents chapters with concise introductions and clear discussions of the underlying pathology that each treatment seeks to reverse; addresses the issues and points to new directions for research, such as the mechanisms of action for the drugs and their development, along with results from clinical trials, main effects, and the side effects of the drugs.